2:11 PM
 | 
Mar 12, 2018
 |  BC Extra  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe. The company also said FDA granted breakthrough therapy designation...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >